Previous studies have shown no correlation between transition of disease status for Philadelphia chromosome-positive (Ph þ ) chronic myelogenous leukemia (CML) and JAK2 V617F gene mutation. 1, 2 Recently, several novel mutations as well as deletion in exon 12 of the JAK2 gene in JAK2 V617F -negative polycythemia vera 3 and JAK2 K607N mutation in acute myeloid leukemia 4 were reported. Because the JAK-STAT pathway plays an important role in the initiation and progression of Ph þ leukemia, 5, 6 we analyzed these novel mutations and deletion of the JAK2 gene among Ph þ CML patients and Ph þ acute leukemia (Ph þ AL). We examined 88 CML patients, three patients with Ph þ acute lymphocytic leukemia and two patients of Ph þ acute biphenotypic leukemia patients. Bone marrow mononuclear cells were obtained from all patients with a written informed consent.
Among the Ph þ CML cases, 72 patients were in the chronic phase, five patients were in the accelerate phase and 11 were in blast crisis (BC). Five Ph þ CML patients had additional chromosome aberrations and three Ph þ CML patients had double Ph þ chromosomes. As for Ph þ CML treatment, 13 had been treated with interferon-a before administration of imatinib and six patients were imatinib resistant.
We first looked for the JAK2 V617F gene mutation by allelicspecific (AS-) PCR and direct sequencing as described in a previous report. 7 No patients with the JAK2 V617F mutation were identified by AS-PCR. Next, we looked for other mutations in exons 12 and 14 of the JAK2 gene by direct sequencing. 3, 7 Neither mutations nor deletions in exons 12 and 14 of the JAK2 gene were detected in these Japanese Ph þ CML and Ph þ AL patients.
The progression of CML to BC requires telomere shortening, genomic instability, differentiation arrest and loss of tumor suppressor, however, the JAK2 mutations might not be required for these processes. Even so, we think that sequencing of the entire JAK2 gene and analysis of the possible abnormalities in the JAK-STAT pathway may be necessary because BCR/ABL directly regulates STAT5. 8 In conclusion, we could not identify any JAK2 gene mutations or deletions among 88 Ph þ CML and Ph þ AL patients. 
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